Blood Test Study for Advanced Cancer and PARP Inhibitor Treatment
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This research study examines circulating tumor cells (cancer cells in the bloodstream) to better understand which patients might benefit from PARP inhibitor drugs. You'll have blood samples collected to help doctors personalize cancer treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have advanced or metastatic breast, prostate, ovarian, or pancreatic cancer
- Your cancer is potentially eligible for PARP inhibitor treatment (a type of cancer drug)
- You have signed an informed consent form and understand the study
- You have valid health insurance or medical coverage
- You do not have another active cancer diagnosis (with some exceptions for skin or cervical cancers)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks for specific gene mutations in the blood of ovarian cancer patients who have a BRCA mutation and are starting first-line maintenance therapy with a PARP inhibitor called Olaparib. It aims to better understand how these mutations may affect treatment response.
This study looks at specific DNA “damage repair” proteins as a marker to understand why some BRCA-mutated breast cancers may resist PARP inhibitor treatment. Your biopsy (or existing biopsy) helps researchers study whether these lab markers relate to how well PARP inhibitors work.
This study uses a special PET scan (FTT-PET) and a blood test (ctDNA) to see if they can predict how well PARP inhibitor therapy works in men with metastatic prostate cancer that has specific genetic mutations. It aims to improve treatment decisions by identifying which patients benefit most from these drugs.
This trial looks at blood samples to measure substances that may reflect cancer (tumor markers). It may help doctors understand cancer better and improve future monitoring, as long as you can safely and regularly take part.
This study is testing a new blood test to find pancreatic cancer early. It looks for tiny bits of cancer DNA floating in your blood, which could help catch the disease before symptoms start.
This trial uses a special blood test to track cancer signals (called ctDNA) during and after treatment for early breast cancer. It aims to see whether monitoring these signals can help guide follow-up and treatment decisions.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.